203787-91-1
203787-91-1
Chemical Structure
Salcaprozate sodium
Synonym(s): SNAC
- No. CAS: 203787-91-1
- Formula:C15H20NNaO4
- Molecular Weight:301.32
IUPAC Name: sodium 8-(2-hydroxybenzamido)octanoate
InChIKey: UOENJXXSKABLJL-UHFFFAOYSA-M
SMILES: O=C(O[Na])CCCCCCCNC(C1=CC=CC=C1O)=O
Biological Activity: Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Salcaprozate sodium | 99.95% | Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salcaprozate sodium (Standard) | 99.91% | Salcaprozate (sodium) (Standard) is the analytical standard of Salcaprozate (sodium). This product is intended for research and analytical applications. Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salcaprozate-d4 sodium | 99.72% | Salcaprozate-d4 (sodium) is a deuterated labeled Salcaprozate (sodium). Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.79
HY-4017215-CNAC -
Similarity Score 0.78
HY-1569575-CNAC disodium -
Similarity Score 0.69
HY-W160298N-Cbz-7-Aminoheptanoic acid -
Similarity Score 0.68
HY-13506GM344 (GMP) -
Similarity Score 0.67
HY-W0138776-(Benzyloxycarbonylamino)caproic acid -
Similarity Score 0.67
HY-117394MD 85 -
Similarity Score 0.65
HY-W013521Hexyl salicylate -
Similarity Score 0.65
HY-W097127Z-5-Ava-OH -
Similarity Score 0.64
HY-17568Nonivamide -
Explore the MedChemAI to find more analogs
References
- [1]. Riley MGI, et, al. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol. Jul-Aug 2009; 28(4):278-93. [Content Brief]
- [2]. Twarog C, et, al. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C 10). Pharmaceutics. 2019 Feb 13; 11(2):78. [Content Brief]
